Paliperidone (Invega) Discontinuation Symptoms
Stopping paliperidone can lead to re-emergence or worsening of underlying psychotic symptoms (rebound psychosis/relapse) after dose reduction or cessation. [1] Antipsychotic discontinuation can also produce withdrawal-emergent movement and activation symptoms. [2] In pregnancy, paliperidone exposure in the third trimester can be associated with extrapyramidal and/or withdrawal symptoms in neonates. [3]
Psychosis Re-Emergence After Discontinuation
Rebound psychosis is a key discontinuation-associated syndrome after antipsychotic interruption. [1] Clinical manifestations can include rapid worsening or return of psychotic symptoms. [1]
Activation and Psychiatric Symptoms
Withdrawal-related activation symptoms can include agitation and anxiety. [2] Withdrawal-related symptoms can include fear, insomnia, and hallucinations that may be confused with relapse. [2]
Movement-Related Withdrawal Symptoms
Withdrawal-emergent motor symptoms can occur with antipsychotic discontinuation. [2] Reported motor syndromes in antipsychotic withdrawal can include dyskinesia and akathisia. [4] Reported motor syndromes in antipsychotic withdrawal can include dystonia. [4]
Cholinergic-Related Rebound (Less Prominent With Paliperidone)
Cholinergic rebound is described as part of antipsychotic discontinuation syndromes in drug classes with relevant anticholinergic properties. [1] Paliperidone is not primarily an anticholinergic agent, so cholinergic-rebound syndromes are less characteristically expected than with anticholinergic antipsychotics. [1]
Neonatal Extrapyramidal and Withdrawal Symptoms (Third-Trimester Exposure)
Neonates exposed to antipsychotic drugs during the third trimester of pregnancy can develop extrapyramidal and/or withdrawal symptoms after delivery. [3] Reported neonatal symptoms can include agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. [3]
Timing After Dose Reduction or Cessation
Antipsychotic discontinuation effects can appear within about 36–96 hours or later after discontinuation, dose reduction, or switch. [4] Antipsychotic discontinuation effects can persist for weeks. [4]
Clinical Actions for Symptom Control
Persistent or worsening psychotic symptoms after discontinuation are managed with close clinical monitoring and consideration of restarting or adjusting antipsychotic treatment when relapse is suspected. [1] Symptomatic treatment of withdrawal-associated anxiety, agitation, or insomnia may be used in selected cases with short-term agents under clinical supervision. [5]
Warning Signs Requiring Urgent Assessment
Urgent assessment is indicated with severe agitation, emergence of hallucinations, significant insomnia, or marked functional decline suggestive of rebound psychosis. [1] Urgent assessment is indicated with severe movement symptoms such as prominent akathisia, dystonia, or dyskinesia after discontinuation. [4] Urgent assessment is indicated for neonates showing respiratory distress, feeding disorder, or abnormal tone after third-trimester antipsychotic exposure. [3]